Skip to content
Screener

Supernus Pharmaceuticals SUPN Inventories

Inventories at other companies

AbbVie logo
AbbVieABBV
$5.05B+11.6%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-$3.9M-195%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$37.88M+105%
XER
Xeris Biopharma Holdings, Inc.XERS
$80.93M+20.3%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$677.95M+11.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+21.8%
Enterprise value$2.63B+21.5%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryNoncurrent.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemBalance Sheet ClassificationMarch 31, 2026December 31, 2025
(unaudited)
Current inventoryInventories, net$87,062$82,385
Noncurrent inventoryOther Assets23,70930,095
Total$110,771$112,480

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's inventories?
Supernus Pharmaceuticals (SUPN) reported inventories of $23.71M in Q1 2026.
How has Supernus Pharmaceuticals's inventories changed year-over-year?
Supernus Pharmaceuticals's inventories decreased by 52.0% year-over-year, from $49.42M to $23.71M.
What is the long-term trend for Supernus Pharmaceuticals's inventories?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's inventories has grown at a -9.0% compound annual growth rate (CAGR), from $48.33M to $30.1M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.

Ask your AI about Supernus Pharmaceuticals's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude